Overview

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Erlotinib Hydrochloride
Gefitinib
Osimertinib